Accueil › Myélome multiple › Alabama › Birmingham
Essais cliniques pour Myélome multiple à Birmingham, AL
18 études pour Myélome multiple recherchent des participants dans et autour de Birmingham (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Recrutement en coursPhase 1/2
- University of Alabama At Birmingham Hospital, Birmingham
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 3
- Alabama Oncology, Birmingham
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 2
- University of Alabama Birmingham, Birmingham
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1/2
- University of Alabama at Birmingham Hospital, Birmingham
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Recrutement en coursPhase 2
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Recrutement en coursPhase 3
- University of Alabama at Birmingham, Birmingham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 2
- University of Alabama at Birmingham, Birmingham
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Recrutement en coursPhase 1/2
- University of Alabama at Birmingham, Birmingham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Recrutement en coursPhase 1/2
- Research Site, Birmingham
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- University of Alabama at Birmingham, Birmingham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Recrutement en coursPhase 2
- University of Alabama at Birmingham, Birmingham
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- University of Alabama at Birmingham, Birmingham
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
Recrutement en coursPhase 1
- University of Alabama at Birmingham, Birmingham
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Recrutement en coursPhase 2
- University of Alabama at Birmingham, Birmingham
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
Recrutement en cours
- Kirklin Clinic of UAB Hospital, Birmingham
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
Recrutement en coursÉtude observationnelle
- Kirklin Clinic of UAB Hospital, Birmingham
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Recrutement en coursPhase 1
- University of Alabama at Birmingham, Birmingham
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1/2
- UAB Comprehensive Cancer Center, Birmingham
Essais pour Myélome multiple dans d'autres villes
- New York City, NY60 études
- Boston, MA42 études
- Atlanta, GA41 études
- Houston, TX38 études
- Durham, NC37 études
- Nashville, TN32 études
- Denver, CO27 études
- Rochester, MN24 études
- St. Louis, MO24 études
- Columbus, OH24 études
- Baldwin Park, CA23 études
- Chicago, IL22 études
Autres études à Birmingham
- Cancer (tous types)30 études
- Cancer du sein24 études
- Obésité23 études
- Cancer de l'ovaire23 études
- Cancer du poumon non à petites cellules22 études
- Leucémie aiguë myéloïde21 études
- BPCO17 études
- Maladie cardiovasculaire17 études
- Surpoids16 études
- Cancer de l'endomètre16 études
- Diabète de type 216 études
- Mucoviscidose16 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.